The FDA came to Elevar Therapeutics bearing gift ahead of the mid-autumn festival. | The FDA has greenlighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel ...
GSK showed a “totally unacceptable” lack of transparency in its interactions wi | GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory ...
Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established production base for ...
Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness. | Biogen has ...
Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.
Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...
Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said. | Sign-ups for Medicare’s GLP-1 coverage plan ...
Novo may be willing to transition some of its shares to the New York Stock Exchange in an effort to woo U.S. investors. | The Ozempic and Wegovy maker's CEO said he's open to a direct listing of ...
AstraZeneca has re-upped its UNICEF-partnered Young Health Programme (YHP), committing to a new five-year phase that will ...
Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an ...
Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...
As China and the U.S. presently duke it out over biopharma innovation supremacy, a clutch of Europe’s biggest drugmakers are calling on the bloc to not lose sight of its R&D roots. | As China and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results